Kamada Ltd. (NASDAQ:KMDA) Sees Significant Decline in Short Interest

Key Points

• Kamada Ltd. experienced a significant 48.6% decline in short interest in July, with a total of 47,300 shares sold short as of July 31st.
• The company reported $0.13 earnings per share for the quarter, exceeding the consensus estimate of $0.09, although revenue fell short at $44.75 million against an expected $158.59 million.
• Analysts maintain a positive outlook, with Benchmark and Wall Street Zen issuing "buy" and "strong-buy" ratings, respectively, and price targets as high as $15.00 per share.

Kamada Ltd. (NASDAQ:KMDA - Get Free Report) was the target of a significant drop in short interest during the month of July. As of July 31st, there was short interest totaling 47,300 shares, adropof48.6% from the July 15th total of 92,000 shares. Approximately0.2% of the shares of the stock are sold short. Based on an average trading volume of 70,300 shares, the days-to-cover ratio is presently 0.7 days. Based on an average trading volume of 70,300 shares, the days-to-cover ratio is presently 0.7 days. Approximately0.2% of the shares of the stock are sold short.

Kamada Stock Performance

Shares of NASDAQ:KMDA traded down $0.13 during mid-day trading on Monday, reaching $7.22. 58,779 shares of the company's stock were exchanged, compared to its average volume of 133,527. The firm has a market capitalization of $415.19 million, a price-to-earnings ratio of 21.25, a PEG ratio of 0.78 and a beta of 0.93. The business's fifty day moving average price is $7.46 and its 200-day moving average price is $7.06. Kamada has a twelve month low of $5.17 and a twelve month high of $9.15.

Kamada (NASDAQ:KMDA - Get Free Report) last released its earnings results on Wednesday, August 13th. The biotechnology company reported $0.13 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.09 by $0.04. The business had revenue of $44.75 million for the quarter, compared to analyst estimates of $158.59 million. Kamada had a net margin of 11.22% and a return on equity of 7.41%. Analysts predict that Kamada will post 0.23 EPS for the current fiscal year.

Hedge Funds Weigh In On Kamada

Institutional investors have recently made changes to their positions in the stock. JPMorgan Chase & Co. acquired a new position in shares of Kamada during the fourth quarter valued at about $67,000. Trexquant Investment LP bought a new stake in shares of Kamada during the first quarter worth about $82,000. NewEdge Advisors LLC increased its position in shares of Kamada by 54.2% during the fourth quarter. NewEdge Advisors LLC now owns 23,496 shares of the biotechnology company's stock worth $143,000 after acquiring an additional 8,260 shares in the last quarter. Jump Financial LLC bought a new stake in shares of Kamada during the second quarter worth about $219,000. Finally, Geode Capital Management LLC increased its position in shares of Kamada by 5.6% during the fourth quarter. Geode Capital Management LLC now owns 29,289 shares of the biotechnology company's stock worth $178,000 after acquiring an additional 1,549 shares in the last quarter. Institutional investors and hedge funds own 20.38% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the stock. Benchmark reissued a "buy" rating and issued a $15.00 price objective on shares of Kamada in a research note on Thursday, May 15th. Wall Street Zen raised shares of Kamada from a "buy" rating to a "strong-buy" rating in a research note on Wednesday, May 21st. Finally, Sidoti raised shares of Kamada to a "hold" rating in a research note on Thursday, May 8th.

Kamada Company Profile

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.